Structural analysis of HER2 with new active therapeutics
 12 September 2013

The human epidermal growth factor receptor 2 (HER2) is a prominent target for tumor targeting since the malignant growth of carcinomas from multiple tissues is linked to the overexpression of this receptor tyrosine kinase. Patients do already benefit from several anti-HER2 drugs like the monoclonal antibodies trastuzumab (Herceptin®) and pertuzumab (Perjeta®), which have been shown in vitro to act only as a cytostatic agent, but not as a cytotoxic agent. The mainly cytostatic mode of action might promote acquired resistance towards the antibody treatment. New HER2-binders employing alternative mechanisms to abolish HER2-dependent signaling and causing cytotoxic effects could expand and complement existing anti-HER2 therapies.

2 of 82 Page 1 2 3  ... Next 

Popular tags in SelectScience

Buying guides

Write a Review

Join the Global SelectScience Community Today! It’s FREE!

Helping you make informed decisions about the latest lab products and technologies:

  • Be the first to learn about new technologies
  • 10,000+ trusted product reviews from your peers
  • Compare 500,000 products and manufacturers
  • Get exclusive buying tips from experts
  • Find solutions fast: 10,000+ Application Notes, Webinars and Videos

Connect with 250,000 scientists... All in one place!

Become a member today!